308 results on '"Launois R"'
Search Results
52. PGI24 - Cost-Effectiveness Analysis of Rifaximin-Α Administration for the Reduction of the Overt Hepatic Encephalopathy Episodes in Recurrence in France
53. PND2 - Cost-Effectiveness Analysis of Continuous Intraduodenal Levodopa Intestinal Gel Infusion in the Treatment of Advanced and Severe Forms of Parkinson's Disease
54. Structural Validation of the Chronic Venous Insufficiency Quality of Life Questionnaire-14 (CIVIQ-14) : A Confirmatory Factor Analysis
55. Linguistic validation of the 20 item-chronic venous disease quality-of-life questionnaire (CIVIQ-20)
56. PMS88 Mixed Treatment Comparison, Cost-Effectiveness Analysis and Budget Impact Model in the Treatment of Rheumatoid Arthritis After Failure of Conventional Dmard Therapy Using Comprehensive Bayesian Decision Analytical Modelling
57. Construction and international validation of CIVIQ-14 (a short form of CIVIQ-20), a new questionnaire with a stable factorial structure
58. Combien coûte la prise en charge d’un purpura thrombopénique immunologique chronique de l’adulte ? À propos d’une étude monocentrique de 57 cas
59. PRS25 CAN THE FRENCH GATEKEEPING SYSTEM BE COST-EFFECTIVE FOR PATIENTS WITH CHRONIC RESPIRATORY DISORDER?
60. PRS23 FRENCH GATEKEEPING COST-EFFECTIVENESS IMPACT ON CHRONIC PATIENTS TREATED WITH INHALED CORTICOSTEROIDS, IN REAL LIFE
61. PMS32 ASSESSMENT OF THE TOTAL DIRECT MEDICAL COST OF PATIENTS IN SECOND-LINE TNF INHIBITOR THERAPY AND OF THE RESPECT OF CLINICAL PRACTICE RECOMMENDATIONS
62. PUK15 STRESS URINARY INCONTINENCE: ASSESSMENT OF WOMEN'S PREFERENCES
63. PMS21 MIXED TREATMENT COMPARISONS: AN EVIDENCE-BASED BUDGET IMPACT MODEL OF RITUXIMAB (MABTHERA®) AFTER FAILURE OF ONE OR MORE TNF INHIBITOR THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS
64. PCV98 COST-EFFECTIVENESS OF ORGANISED INPATIENT CARE FOR STROKE
65. Modèle d’impact budgétaire lors de l’utilisation du rituximab après échec d’un ou plusieurs anti-TNFα dans le traitement de la polyarthrite rhumatoïde en France
66. Modèle d'impact budgétaire lors de l'utilisation du rituximab après échec d'un ou plusieurs anti-TNFα dans le traitement de la polyarthrite rhumatoïde en France
67. PMH14 PHARMACOECONOMIC POSITIONING OF SERTINDOLE AMONG ANTIPSYCHOTICS IN THE MANAGEMENT OF SCHIZOPHRENIA: THE HUNGARIAN EXPERIENCE
68. PCN14 COST-EFFECTIVENESS STUDY OF AN ASPIRIN CHEMOPREVENTION ASSOCIATED OR NOT WITH A COLONOSCOPIC SURVEILLANCE IN THE COLORECTAL CANCER
69. PCN43 COST-EFFECTIVENESS OF CETUXIMAB (ERBITUX®) IN COMBINATION WITH RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN THE TREATMENT OF LOCALLY ADVANCED HEAD AND NECK CANCER IN FRANCE
70. PEY9 ASSESSMENT OF THE COST-EFFECTIVENESS OF TRAVOPROST VERSUS LATANOPROST, AS SINGLE AGENTS FOR GLAUCOMA TREATMENT IN FRANCE
71. CN4 COST MINIMISATION ANALYSIS OF FIRST LINE POLYCHEMOTHERAPY REGIMENS IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER
72. MC2 IMPACT OF THE PROPENSITY SCORE ESTIMATION METHOD WHEN MATCHING PATIENTS TO REDUCE RECRUITMENT BIAS IN OBSERVATIONAL STUDIES
73. PCN7 COST ANALYSIS OF 3-YEARS FOLLOW-UP OF A TRASTUZUMAB TREATED COHORT
74. PCN20 ORAL AND INTRAVENOUS CHEMOTHERAPY FOR FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE UK NHS SYSTEM
75. PCN3 POPULATION-BASED BUDGET IMPACT MODEL OF APREPITANT (EMEND) IN HIGHLY EMETOGENIC CISPLATINE-BASED CHEMOTHERAPY
76. PEY3 INTRA-OCULAR PRESSURE (IOP) CONTROL OF LATANOPROST AND TRAVOPROST MONOTHERAPY IN DAILY PRACTICE
77. PCN6 POPULATION-BASED BUDGET IMPACT MODEL OF APREPITANT (EMEND) IN MODERATELY EMETOGENIC CHEMOTHERAPY (MEC)
78. PCN36 A COST UTILITY ANALYSIS OF FIRST-LINE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF METASTATIC BREAST CANCERAFTERANTHRACYCLINE FAILURE
79. PIN12 ASSESSEMENT OF THE EFFECT OF DROTRECOGIN ALPHA (ACTIVATED)TREATMENT OF SEVERE SEPSIS ON BLEEDING EVENTS WITH COUNT MODELS
80. IN2 ASSESSEMENT OF THE ADDITIONAL COST OF DROTRECOGIN ALFA (ACTIVATED) RELATIVE TO STANDARD CARE IN THE TREATMENT OF SEVERE SEPSIS IN A MULTICENTIC OBSERVATIONAL STUDY IN FRANCE
81. PIN1 ASSESSING THE EXTERNAL VALIDITY OF DROTRECOGIN ALFA (ACTIVATED) CLINICAL TRIALS IN AN OBSERVATIONAL STUDY USING PROPENSITY SCORE MATCHING TO REDUCE RECRUITMENT BIAS
82. P-522 A cost minimization analysis of first-line polychemotherapyregimens in the treatment of advanced non-small cell lung cancer
83. CS4 ANTIPSYCHOTIC PATTERNS AND TREATMENT COST IN FRANCE
84. MH2 MODELING ANTIPSYCHOTICS MARKET SHARE EVOLUTION TREATMENT
85. PCV68 POPULATION IMPACT OF LOSARTAN USE ON STROKE IN FRANCE
86. PCNI2 COST EFFECTIVENESS OF AN ASPIRIN CHEMOPREVENTION AND/OR COLONOSCOPIC SURVEILLANCE IN THE COLORECTAL CANCER
87. PCN23 A COST MINIMIZATION ANALYSIS OF FIRST-LINE POLYCHEMOTHERAPY REGIMENS IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
88. PCV70 DECISION ANALYSIS AND COSTS OF LOW MOLECULAR WEIGHT HEPARINS: A CASE STUDY IN FRANCE
89. PAA6 IMPACT OF A DISEASE MANAGEMENT PROGRAM ON CONTROL OF ASTHMA IN NORMANDY
90. PCNI5 GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIALS (GREAT2): A PATIENT-LEVEL COST COMPARISON OF THREE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN FRANCE
91. PCN7 ORAL VINORELBINE IN THE TREATMENT OF NON SMALL CELL LUNG CANCER
92. 991 Serial monitoring of serum HER-2 extracellular domain (H-ECD) during herceptin-taxol chemotherapy (CT) for metastatic breast cancer (MBC) pts: preliminary results from the French experience (HER.ME.S protocol)
93. PRP10 A DISEASE MANAGEMENT PROGRAM IN FRANCE: LESSONS FROM THE RESALIS EXPERIMENT 18 MONTHS BEFORE AND 12 MONTHS AFTER PUBLIC HEALTH INTERVENTIONS
94. Quality of life (Spain and France): Validation of the Chronic Venous Insufficiency Questionnaire (CIVIQ)
95. PHP6: INSURANCE CLAIMS AS A DEVICE FOR MEASURING THE PHARMACISTS SUBSTITUTION RIGHT IN A FRENCH DEPARTMENT
96. MH6: MODELLING THE COSTS OF ILLNESS AND THE COSTS OF RELAPSE IN THE MANAGEMENT OF SCHIZOPHRENIA IN THE UK
97. CN5: A SPECIFIC QUALITY OF LIFE SCALE IN UPPER LIMB LYMPHOEDEMA: THE ULL-27 QUESTIONNAIRE
98. PCV23: MODELLING THE COSTS OF ILLNESS IN THE MANAGEMENT OF CEREBROVASCULAR ACCIDENTS IN FRANCE
99. Linguistic validation of the 20 item-chronic venous disease quality-of-life questionnaire (CIVIQ-20)
100. Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalised patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.